title: Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer.
abstract: BACKGROUND
  The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Between June 2004 and September 2008, sixty-six patients with multiple brain metastases from NSCLC were enrolled in this prospective study. All patients were required to have 2-3 brain metastases and Karnofsky performance status (KPS) > or = 70. WBRT treatment dose was 30 Gy in 10 fractions followed by SRS. A matched control population treated with WBRT alone to a dose of 30 Gy in 10 fractions was used for comparison.
  
  
  RESULTS
  The median survival was 10.3 months in the WBRT plus SRS group and 7.2 months in the WBRT group (p=0.005). The 6-month and 12-month survival rates were 90% and 38% in the SRS plus WBRT group and 84% and 19% in the WBRT group (p=0.01). Stable extracranial disease and KPS were significant predictive factors of survival in both groups (p=0.001). Death due to neurological causes occurred in 18% and 35% of patients treated with WBRT plus SRS and WBRT (p=0.02), respectively. Disease control in the brain was 10 months in the SRS plus WBRT group and 7 months in the WBRT group (p=0.001); the 6-month and 12-month control rates were 82% and 42% for WBRT plus SRS, and 75% and 18% for WBRT (p=0.001), respectively. The 6-month and 12-month control rates of treated lesions (local control) were 90% and 47% in the WBRT group, and 100% and 93% in the WBRT plus SRS group (p=0.001).
  
  
  CONCLUSIONS
  WBRT plus SRS is a safe, minimally invasive and well-tolerated treatment for patients with up to three brain metastases from NSCLC. The treatment is associated with longer survival and better disease control in comparison with WBRT alone. Survival benefits need to be confirmed by large randomized studies.
authors.affiliation: Department of Radiotherapy Oncology, Sant' Andrea Hospital, University of Rome 'La Sapienza' Via di Grottarossa 1035, 00189 Rome, Italy. Giuseppe.Minniti@ospedalesantandrea.it
authors.forename: G
authors.initials: G
authors.lastname: Minniti
authors.forename: M
authors.initials: M
authors.lastname: Salvati
authors.forename: R
authors.initials: R
authors.lastname: Muni
authors.forename: G
authors.initials: G
authors.lastname: Lanzetta
authors.forename: M F
authors.initials: MF
authors.lastname: Osti
authors.forename: E
authors.initials: E
authors.lastname: Clarke
authors.forename: A
authors.initials: A
authors.lastname: Costa
authors.forename: A
authors.initials: A
authors.lastname: Bozzao
authors.forename: G
authors.initials: G
authors.lastname: Trasimeni
authors.forename: R Maurizi
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D015996:Survival Rate